share_log

4: Statement of changes in beneficial ownership of securities-Officer WORLAND STEPHEN T

4: Statement of changes in beneficial ownership of securities-Officer WORLAND STEPHEN T

4：持股變動聲明-高管 WORLAND STEPHEN T
美股sec公告 ·  05/17 16:03
Moomoo AI 已提取核心訊息
On May 15, 2024, Stephen T. Worland, the Chief Executive Officer of eFFECTOR Therapeutics, Inc. (EFTR), completed a purchase of 1,806 shares of common stock at a price of $1.683 per share. Following this transaction, Worland's direct holdings in the company increased to 12,494 shares. The transaction is classified as a grant, award, or other acquisition, according to the transaction code description. In addition to his direct holdings, Worland also has an indirect beneficial ownership of 22,493 shares through a trust.
On May 15, 2024, Stephen T. Worland, the Chief Executive Officer of eFFECTOR Therapeutics, Inc. (EFTR), completed a purchase of 1,806 shares of common stock at a price of $1.683 per share. Following this transaction, Worland's direct holdings in the company increased to 12,494 shares. The transaction is classified as a grant, award, or other acquisition, according to the transaction code description. In addition to his direct holdings, Worland also has an indirect beneficial ownership of 22,493 shares through a trust.
2024年5月15日，Effector Therapeutics, Inc.（EFTR）首席執行官斯蒂芬·沃蘭德以每股1.683美元的價格完成了對1,806股普通股的收購。在這筆交易之後，Worland在該公司的直接持股量增加到12,494股。根據交易代碼描述，該交易被歸類爲贈款、獎勵或其他收購。除了直接持有外，沃蘭德還通過信託擁有22,493股股票的間接實益所有權。
2024年5月15日，Effector Therapeutics, Inc.（EFTR）首席執行官斯蒂芬·沃蘭德以每股1.683美元的價格完成了對1,806股普通股的收購。在這筆交易之後，Worland在該公司的直接持股量增加到12,494股。根據交易代碼描述，該交易被歸類爲贈款、獎勵或其他收購。除了直接持有外，沃蘭德還通過信託擁有22,493股股票的間接實益所有權。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息